leadf
logo-loader
OTCQB:BETRF CSE:BETR

BetterLife Pharma Inc

Receive alerts
Market:
OTCQB
Market Cap:
$44.66 m
Price
0.89 USD
Change
-21.50%
52 weeks high
2.21
52 weeks low
0.10

In brief

BLife Therapeutics, a wholly-owned subsidiary of BetterLife Pharma Inc., is focused on the development of its patent pending Interferon formula, AP-003, for the treatment and prevention of severe COVID-19 disease. It’s parent, Better Life Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of Interferon therapeutics to meet unmet needs for patients worldwide with a pipeline of HPV-cervical dysplasia (AP-001) which has completed Phase 2 and AP-002, an oral gallium-based novel small molecule, US IND approved and has started Phase 1-2 in October 2019 in the US in cancer patients with advanced or recurrent solid tumours.

Snapshot

CEO Ahmad Doroudian said the firm is “aggressively developing” next generation psychedelic products like TD-0148A, to become a leader in a market with a projected $6.85 billion value by 2027

Insight Widest with the analysis, Proactive gives perspectives that others don't.

BetterLife Pharma on promising path with Altum merger and Phase 2 trial of AP-003 drug to fight coronavirus

The group’s CEO Ahmad Doroudian expects the AP-003 Phase 2 trial to be completed in the next three-to-six months, and approved under emergency use authorization

on 15/7/20